BDP9066 - ≥98% , CAS No.2226507-04-4

CAS: 2226507-04-4 Cat. No.: B651933 Molecular Weight: 348.44 PubChem CID: 132275018
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
5mg
B651933-5mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$300.90
10mg
B651933-10mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$500.90
25mg
B651933-25mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,100.90
50mg
B651933-50mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,900.90
100mg
B651933-100mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$3,300.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.

In Vitro

BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:IC50: 64 nM (MRCKβ in SCC12 cells), Ki: 0.0136 nM/0.0233 nM (MRCKα/β)

Specifications

Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeu
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥98%
Names and Identifiers
Canonical SmilesC1CCNC2(C1)CCCN(C2)C3=C4C(=CNC4=NC=C3)C5=NC=NC=C5
IUPAC Name(6S)-8-(3-pyrimidin-4-yl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1,8-diazaspiro[5.5]undecane
InChIKeyUELSMLDRSQFVHG-FQEVSTJZSA-N
INCHI1S/C20H24N6/c1-2-8-25-20(6-1)7-3-11-26(13-20)17-5-10-22-19-18(17)15(12-23-19)16-4-9-21-14-24-16/h4-5,9-10,12,14,25H,1-3,6-8,11,13H2,(H,22,23)/t20-/m0/s1
PubChem CID 132275018
MeSH Entry Terms (6S)-8-(3-(4-Pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-1,8-diazaspiro(5.5)undecane;1,8-Diazaspiro(5.5)undecane, 8-(3-(4-pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-, (6S)-;BDP9066
Molecular Weight 348.44

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
ClassAzaspirodecane derivatives
SubclassNot available
Intermediate Tree Nodes Not available
Direct ParentAzaspirodecane derivatives
Alternative Parents Pyrrolopyridines  Dialkylarylamines  Aminopyridines and derivatives  Substituted pyrroles  Pyrimidines and pyrimidine derivatives  Piperidines  Heteroaromatic compounds  Dialkylamines  Azacyclic compounds  Organopnictogen compounds  Hydrocarbon derivatives  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Azaspirodecane - Pyrrolopyridine - Dialkylarylamine - Tertiary aliphatic/aromatic amine - Aminopyridine - Substituted pyrrole - Pyrimidine - Pyridine - Piperidine - Heteroaromatic compound - Pyrrole - Tertiary amine - Azacycle - Secondary amine - Secondary aliphatic amine - Organic nitrogen compound - Organopnictogen compound - Hydrocarbon derivative - Organonitrogen compound - Amine - Aromatic heteropolycyclic compound
DescriptionThis compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom.
External Descriptors Not available
3D Structure
Interactive Chemical Structure Model





Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
SolubilityDMSO : 10 mg/mL (28.70 mM; Need ultrasonic)
Molecular Weight348.400 g/mol
XLogP32.200
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass348.206 Da
Monoisotopic Mass348.206 Da
Topological Polar Surface Area69.700 Ų
Heavy Atom Count26
Formal Charge0
Complexity487.000
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Citations of This Product
References
1. Sufang Xu, Xin Zhang, Jingru Sun, Man Qin, Huarong Du, Bing Luo.  (2026)  Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3.  ImmunoTargets and Therapy,      [PMID:] [10.2147/ITT.S565624]
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.